Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sherene Loi

Showing results (191-200 of 325) with videos related to

Pageof 33
Sort By:
Cancer Research|May 28, 2016
The E3-ligase E6AP Represses Breast Cancer Metastasis via Regulation of ECT2-Rho SignalingMariam Mansour, Sue Haupt, Ai-Leen Chan, et al.
Journal of the National Cancer Institute|June 7, 2021
PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast CancerHope S Rugo, Sherene Loi, Sylvia Adams, et al.
Breast Cancer Research and Treatment|May 29, 2019
Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trialMatteo Lambertini, Christine Campbell, Richard D Gelber, et al.
Molecular Endocrinology (Baltimore, Md.)|January 8, 2013
Research resource: nuclear receptors as transcriptome: discriminant and prognostic value in breast cancerGeorge E O Muscat, Natalie A Eriksson, Karen Byth, et al.
The New England Journal of Medicine|October 23, 2018
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast CancerNicholas C Turner, Dennis J Slamon, Jungsil Ro, et al.
The New England Journal of Medicine|October 23, 2018
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast CancerPeter Schmid, Sylvia Adams, Hope S Rugo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2026
DESTINY-Breast08: a phase 1b study of trastuzumab deruxtecan in combination with other anticancer therapies in patients with HER2-low metastatic breast cancerKomal Jhaveri, Sherene Loi, Erika Hamilton, et al.
NPJ Breast Cancer|July 10, 2025
Advancing equitable access to innovation in breast cancerSeamus O'Reilly, Ines Vaz Luis, Virginie Adam, et al.
BMC Medicine|August 4, 2015
Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancerAmir Sonnenblick, Sylvain Brohée, Debora Fumagalli, et al.
Cancer Research|June 5, 2019
Retraction: The E3-ligase E6AP Represses Breast Cancer Metastasis via Regulation of ECT2-Rho SignalingMariam Mansour, Sue Haupt, Ai-Leen Chan, et al.
Pageof 33

Showing results (191-200 of 325) with videos related to

Sort By:
Pageof 33
Cancer Research|May 28, 2016
The E3-ligase E6AP Represses Breast Cancer Metastasis via Regulation of ECT2-Rho SignalingMariam Mansour, Sue Haupt, Ai-Leen Chan, et al.
Journal of the National Cancer Institute|June 7, 2021
PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast CancerHope S Rugo, Sherene Loi, Sylvia Adams, et al.
Breast Cancer Research and Treatment|May 29, 2019
Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trialMatteo Lambertini, Christine Campbell, Richard D Gelber, et al.
Molecular Endocrinology (Baltimore, Md.)|January 8, 2013
Research resource: nuclear receptors as transcriptome: discriminant and prognostic value in breast cancerGeorge E O Muscat, Natalie A Eriksson, Karen Byth, et al.
The New England Journal of Medicine|October 23, 2018
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast CancerNicholas C Turner, Dennis J Slamon, Jungsil Ro, et al.
The New England Journal of Medicine|October 23, 2018
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast CancerPeter Schmid, Sylvia Adams, Hope S Rugo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2026
DESTINY-Breast08: a phase 1b study of trastuzumab deruxtecan in combination with other anticancer therapies in patients with HER2-low metastatic breast cancerKomal Jhaveri, Sherene Loi, Erika Hamilton, et al.
NPJ Breast Cancer|July 10, 2025
Advancing equitable access to innovation in breast cancerSeamus O'Reilly, Ines Vaz Luis, Virginie Adam, et al.
BMC Medicine|August 4, 2015
Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancerAmir Sonnenblick, Sylvain Brohée, Debora Fumagalli, et al.
Cancer Research|June 5, 2019
Retraction: The E3-ligase E6AP Represses Breast Cancer Metastasis via Regulation of ECT2-Rho SignalingMariam Mansour, Sue Haupt, Ai-Leen Chan, et al.
Pageof 33